Unfortunately, none of Nate's picks are portfolio worthy just yet. Martek Biosciences (Nasdaq:MATK) is a good play on Omega 3 fatty acid and its acceptance into the mainstream of nutrition. It dipped below its 50 day M.A., like almost all stocks, on Friday but I will keep my eye on this story. He listed Wizzard Software (WIZD.OB) as a take-over play because they have become the largest "podcasting" company in the world. Also below its 50 day M.A., but at $2.52 it may make the Portfolio soon. Finally, Celgene (Nasdaq:CELG) has hit some hard times lately, but is a quality stock that needs a little momentum before it makes the Portfolio.
Listen In!
http://www.wallstreetreporter.com/page.php?page=featured&id=27517
Subscribe to:
Post Comments (Atom)
1 comment:
Interesting stocks great news reviews.
Post a Comment